EGFR and non-small cell lung carcinoma: For patients with locally advanced or metastatic NSCLC with EGFR mutations (Ex19del or L858R) (NCT06120140), compared to those receiving osimertinib, patients treated with amivantamab plus lazertinib had longer mPFS (23.7 months vs. 16.6 months, HR=0.7) and longer mDoR (25.8 months vs. 16.8 months) (44, 45).